Physician profile
Mark W Thomas
NPI 1750304796
$2,801.08
in general payments reported to CMS, 2019-2025
29 companies · $436 in 2025
The $436 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $71.82 · 2021: $130 · 2022: $459 · 2023: $554 · 2024: $837 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,764 · Education: $62.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,764.23 |
| Education | $62.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $368.93 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $342.86 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $326.35 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Supernus Pharmaceuticals, INC. | $225.29 | 2022-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $196.18 | 2019-2025 | Dyanavel Xr |
| Alk-Abello, INC | $172.30 | 2023-2025 | Ragwitek, Odactra, Grastek |
| Pfizer INC. | $171.72 | 2019-2025 | |
| Sanofi Pasteur INC. | $164.51 | 2019-2025 | |
| Kaleo, INC. | $111.95 | 2022-2023 | Auvi-Q |
| Cranial Technologies, INC | $111.49 | 2019-2024 | Doc Band |
| Genentech USA, INC. | $93.67 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $91.52 | 2025 | Jornay Pm |
| Seqirus USA INC | $51.88 | 2022-2025 | Flucelvax |
| Glaxosmithkline, LLC. | $50.31 | 2019-2023 | Bexsero |
| Otto Bock Healthcare LP | $42.55 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $32.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.95 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $23.98 | 2023 | Flumist Quadrivalent |
| Neurocrine Biosciences, INC. | $23.37 | 2024 | |
| Avion Pharmaceuticals | $21.49 | 2023 | Methylphenidate Hydrochloride |
| Neos Therapeutics, LP | $20.77 | 2024 | Cotempla Xr-Odt |
| Ars Pharmaceuticals Operations, INC. | $20.73 | 2025 | Neffy |
| Vertical Pharmaceuticals, LLC | $20.16 | 2019 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Verrica Pharmaceuticals INC. | $18.21 | 2024 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $14.73 | 2022 | |
| Adlon Therapeutics L.P. | $14.04 | 2021 | |
| Mylan Pharmaceuticals INC. | $12.16 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.